{
    "organizations": [],
    "uuid": "8d62a43c6af011775b9c16776f185b522f48c60b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/shire-results/shire-posts-16-pct-rise-in-full-year-earnings-sees-slower-growth-in-2018-idUSFWN1Q4112",
    "ord_in_thread": 0,
    "title": "Shire ‚Äçposts 16 pct rise in full-year earnings, sees slower growth in 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LONDON, Feb 14 (Reuters) - Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.\nThe London-listed company on Wednesday reported full-year revenue of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per ADS of $15.15, which came in towards the top of its guidance.\nReporting by Paul Sandle; editing by James Davey\n ",
    "published": "2018-02-14T20:16:00.000+02:00",
    "crawled": "2018-02-15T20:50:16.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "london",
        "feb",
        "reuters",
        "shire",
        "pharma",
        "firm",
        "splitting",
        "rare",
        "disease",
        "hyperactivity",
        "drug",
        "two",
        "unit",
        "said",
        "sale",
        "would",
        "grow",
        "digit",
        "profit",
        "lower",
        "percentage",
        "top",
        "line",
        "year",
        "earnings",
        "per",
        "share",
        "rose",
        "percent",
        "company",
        "wednesday",
        "reported",
        "revenue",
        "billion",
        "percent",
        "diluted",
        "earnings",
        "per",
        "ad",
        "came",
        "towards",
        "top",
        "guidance",
        "reporting",
        "paul",
        "sandle",
        "editing",
        "james",
        "davey"
    ]
}